Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-751 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | Pemetrexed + ABT-751 |
| B | PLACEBO_COMPARATOR | Pemetrexed + placebo |
| Name | Type | Description |
|---|---|---|
| ABT-751 | DRUG | 200 mg ABT-751 daily for 14 days every 21 days |
| pemetrexed | DRUG | Standard pemetrexed every 21 days |
| placebo | DRUG | Placebo daily for 14 days every 21 days |
Inclusion Criteria: * Pathologically documented NSCLC * Locally advanced (Stage III) or metastatic (Stage IV) NSCLC * Only one prior anti-tumor treatment regimen in the non-curative setting (i.e., 2nd-line therapy) * Only one prior anti-tumor treatment regimen in the curative setting * Progressive ...
Top 20 of 75 competitors
ABT-751 is an investigational small molecule being studied for the treatment of lung cancer, specifically advanced non-small cell lung cancer (NSCLC). It has been evaluated in combination with Alimta (pemetrexed) in adult patients with advanced disease. ABT-751 has not been approved for any indication and remains in clinical development.
ABT-751 targets tubulin, binding to beta-tubulin subunits including TUBB1, TUBB3, TUBB4A, TUBB4B, and TUBB8. It acts as a tubulin inhibitor, disrupting microtubule dynamics. This mechanism interferes with cell division and is the basis for its investigation as an anticancer agent in oncology.
ABT-751 is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the clinical program evaluating ABT-751 in lung cancer.
ABT-751 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any regulatory authority for any indication. The completed trial was a Phase 1/2 study, and no active trials are currently listed.
ABT-751 has been studied in one completed clinical trial, NCT00297089, titled a Phase 1/2 study evaluating ABT-751 in combination with Alimta in advanced non-small cell lung cancer. The trial enrolled 165 patients across the United States, Czechia, Greece, Hungary, Netherlands, and Slovakia. It was randomized, double-blind, and placebo-controlled.